$8.58
+0.11
(+1.3%)▲
3.16%
Downside
Day's Volatility :4.71%
Upside
1.61%
24.24%
Downside
52 Weeks Volatility :55.9%
Upside
41.79%
Period | Inmune Bio Inc | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | -24.98% | 6.5% | 0.0% |
6 Months | -29.88% | 7.1% | 0.0% |
1 Year | -0.35% | 9.8% | 0.0% |
3 Years | -47.78% | 14.2% | -20.2% |
Market Capitalization | 163.4M |
Book Value | $1.57 |
Earnings Per Share (EPS) | -1.92 |
Wall Street Target Price | 19.67 |
Profit Margin | 0.0% |
Operating Margin TTM | -78692.86% |
Return On Assets TTM | -35.53% |
Return On Equity TTM | -81.82% |
Revenue TTM | 131.0K |
Revenue Per Share TTM | 0.01 |
Quarterly Revenue Growth YOY | -63.2% |
Gross Profit TTM | 374.0K |
Diluted Eps TTM | -1.92 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -2.6 |
EPS Estimate Next Year | -2.55 |
EPS Estimate Current Quarter | -0.53 |
EPS Estimate Next Quarter | -0.63 |
What analysts predicted
Upside of 129.25%
Sell
Neutral
Buy
Inmune Bio Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Inmune Bio Inc | 16.19% | -29.88% | -0.35% | -47.78% | -63.13% |
![]() Moderna, Inc. | -1.67% | 18.26% | -0.21% | -64.15% | 752.69% |
![]() Regeneron Pharmaceuticals, Inc. | -0.46% | 13.21% | 45.59% | 84.19% | 244.2% |
![]() Novo Nordisk A/s | -11.0% | 18.31% | 61.56% | 186.46% | 423.59% |
![]() Vertex Pharmaceuticals Incorporated | 3.85% | 14.43% | 39.88% | 147.45% | 195.07% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Inmune Bio Inc | NA | NA | NA | -2.6 | -0.82 | -0.36 | NA | 1.57 |
![]() Moderna, Inc. | 24.73 | NA | 0.0 | -7.19 | -0.38 | -0.16 | NA | 33.47 |
![]() Regeneron Pharmaceuticals, Inc. | 31.35 | 31.35 | 1.46 | 44.44 | 0.15 | 0.08 | NA | 250.15 |
![]() Novo Nordisk A/s | 44.28 | 44.28 | 2.36 | 3.43 | 1.0 | 0.25 | 0.01 | 22.18 |
![]() Vertex Pharmaceuticals Incorporated | 31.85 | 31.85 | 0.53 | 16.98 | 0.24 | 0.13 | NA | 71.8 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Inmune Bio Inc | Buy | $163.4M | -63.13% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $45.3B | 752.69% | 24.73 | -115.82% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $116.9B | 244.2% | 31.35 | 29.45% |
![]() Novo Nordisk A/s | Buy | $572.0B | 423.59% | 44.28 | 36.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $126.7B | 195.07% | 31.85 | 39.46% |
Insights on Inmune Bio Inc
Revenue is down for the last 4 quarters, 46.0K → 14.0K (in $), with an average decrease of 30.5% per quarter
Netprofit is down for the last 2 quarters, -8.40M → -11.02M (in $), with an average decrease of 31.1% per quarter
In the last 1 year, Novo Nordisk A/s has given 61.6% return, outperforming this stock by 62.0%
In the last 3 years, Novo Nordisk A/s has given 186.5% return, outperforming this stock by 234.3%
Vanguard Group Inc
BlackRock Inc
Mccormack Advisors International
Rhenman Partners Asset Management AB
Geode Capital Management, LLC
Millennium Management LLC
inmune bio inc. is a clinical stage immuno-oncology company focused on harnessing the patient’s immune system to treat cancer. inkmune, the company’s lead product, primes patient’s nk cells (natural killer cells) to kill cancer. inmune is targeting residual disease, the cancer cells that survive initial treatments that return to cause the cancer relapse. by controlling residual disease, patients may live longer. using a novel mechanism of action and a precision medicine approach, inkmune therapy should enhance nk cells’ ability to eliminate residual disease.
Organization | Inmune Bio Inc |
Employees | 11 |
CEO | Dr. Raymond Joseph Tesi M.D. |
Industry | Medical Specialties |
A Spac I Acquisition Corp
$8.58
+1.3%
Keyarch Acquisition Corp
$8.58
+1.3%
Connexa Sports Technologies Inc
$8.58
+1.3%
Us Value Etf
$8.58
+1.3%
First Wave Biopharma Inc
$8.58
+1.3%
Global X Msci Next Emerging
$8.58
+1.3%
Fat Projects Acquisition Corp
$8.58
+1.3%
Capital Link Global Fintech
$8.58
+1.3%
Applied Uv Inc
$8.58
+1.3%